Nigel J Rulewski
Quintiles, Inc. , USA
Biography
Dr. Nigel Rulewski has 25+ years’ experience in Drug Development and Regulatory Affairs, in both large and small pharma, Venture Capital and Pharmaceutical Business Development. He is presently VP, Strategic Drug Development Group and Head, Biosimilar Center of Excellence, at Quintiles.He has planned the development of biosimilar versions of EPO, GCSF, peg-GCSF, Remicade, Humira, Enbrel, Rituximab, Avastin and Herceptin. Dr Rulewski earned his medical degree at St Bartholomew’s Medical School, University of London and also holds a Diploma in Child Health, Royal College of Physicians and a Diploma of Royal College of Obstetricians and Gynecologists
Abstract
Abstract : Issues in the Clinical Development of the first Wave of Biosimilars